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Background: Several (neo)adjuvant treatments for patients with HER2-positive breast 
cancer have been compared in different randomized clinical trials. Since it is not feasible 
to conduct adequate pairwise comparative trials of all these therapeutic options, net-
work meta-analysis offers an opportunity for more detailed inference for evidence-based 
therapy.
Methods: Phase II/III randomized clinical trials comparing two or more different (neo)
adjuvant treatments for HER2-positive breast cancer patients were included. Relative 
treatment effects were pooled in two separate network meta-analyses for overall survival 
(OS) and disease-free survival (DFS).
Results: 17 clinical trials met our eligibility criteria. Two different networks of trials 
were created based on the availability of the outcomes: OS network (15 trials: 37,837 
patients); and DFS network (17 trials: 40,992 patients). Two studies—the ExteNET and 
the NeoSphere trials—were included only in this DFS network because OS data have not 
yet been reported. The concept of the dual anti-HER2 blockade proved to be the best 
option in terms of OS and DFS. Chemotherapy (CT) plus trastuzumab (T) and lapatinib 
(L) and CT + T + Pertuzumab (P) are probably the best treatment options in terms of 
OS, with 62.47% and 22.06%, respectively. In the DFS network, CT + T + Neratinib 
(N) was the best treatment option with 50.55%, followed by CT + T + P (26.59%) and 
CT + T + L (20.62%).
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Conclusion: This network meta-analysis suggests that dual anti-HER2 blockade with 
trastuzumab plus either lapatinib or pertuzumab are probably the best treatment options 
in the (neo)adjuvant setting for HER2-positive breast cancer patients in terms of OS gain. 
Mature OS results are still expected for the Aphinity trial and for the sequential use of 
trastuzumab followed by neratinib, the treatment that showed the best performance in 
terms of DFS in our analysis.
Keywords: breast cancer, HeR2/eRBB2, adjuvant treatment, neoadjuvant treatment, meta-analysis, network 
meta-analysis
iNTRODUCTiON
Breast cancer is the most common malignancy among women 
worldwide accounting for 2.4 million new cases and 523,000 
deaths yearly (1). Approximately 15–20% of breast cancers are 
classified as HER2-positive (HER2+), a subgroup of tumors with 
a more aggressive clinical phenotype and worse prognosis due 
to unregulated cell growth and abnormal survival mediated by 
overexpression of the HER2 protein (2–8).
Currently, there are multiple effective therapies blocking the 
HER2-pathway in different manners (intra or extracellular). Since 
the approval of the first HER2-targeted therapy, trastuzumab, 
in 2001, other anti-HER2-targeted agents have been developed 
and tested in the metastatic and in the (neo)adjuvant settings, 
including lapatinib, pertuzumab, neratinib, and TDM1 (9, 10). 
In the adjuvant setting, trastuzumab was the cornerstone of the 
anti-HER2 therapy for the treatment of HER2+ breast cancer 
until recently, when results of T + P and neratinib after T were 
approved (11–13).
Despite the efficacy of trastuzumab, recurrences do occur 
and present a serious clinical problem for HER2+ patients since 
tumors may exhibit de novo or acquired resistance (14–20). To 
overcome trastuzumab resistance, it has been combined with 
different chemotherapies and other HER2-targeted agents, 
a strategy known as dual anti-HER2 blockade. Unfortunately, it is 
not feasible to have adequate pairwise comparative data for all the 
available treatment options because the number of possible head-
to-head comparisons directly expands in a quadratic proportion 
with the availability of effective agents (21).
Mixed Treatment Comparison (MTC) meta-analysis, a 
generalization of pairwise meta-analysis, offers an opportunity 
to a more detailed inference in clinical situations where there are 
many different treatment options. By combining direct and indi-
rect evidence to compare multiple treatment arms across studies 
(with the proviso that there is at least one common arm between 
them), it extends beyond the standard and critical pairwise meta-
analysis constraint of only incorporating information from two 
directly compared arms (21–23).
Within the current context of personalized medicine, where 
physicians and policy makers must base their decisions on the 
highest level of available evidence in order to choose one out of 
multiple available treatment options, the present study aims to 
summarize the network of evidence supporting the treatment of 
patients with early and locally advanced HER2+ breast cancer in 
terms of overall survival (OS) and disease-free survival (DFS).
MATeRiALS AND MeTHODS
Search Strategy
MEDLINE, EMBASE, and Cochrane Central Register of 
Controlled Trials were searched without any restriction of lan-
guage or year of publication. Different search algorithms were 
used for each database. Detailed search strategies are described 
in the Supplementary Material A. To avoid overlooking the 
results of recent neoadjuvant and adjuvant trials, we also con-
ducted an electronic search of the main international congress 
abstracts: the American Society of Clinical Oncology, the San 
Antonio Breast Cancer Symposium, the European Society for 
Medical Oncology (ESMO), and the St. Gallen International 
Breast Cancer Conference. Additionally, other relevant trials 
were sought by reviewing the reference lists of the selected 
trials.
Selection Criteria
The pre-specified eligibility criteria for trials included in this 
review were as follows: phase II or III randomized controlled 
trials that compared CT plus any anti-HER2 therapy with CT alone 
or any different combination of CT plus anti-HER2 therapy in the 
adjuvant or neoadjuvant settings (criteria for HER2-positivity as 
standard for HER2 adjuvant and neoadjuvant trials). Trials with 
two or more treatment arms were considered eligible for this 
work. Following the GCP (Good Clinical Practice) guidelines, 
endocrine therapy was offered to patients with hormonal receptor 
positive tumors as part of their adjuvant treatment in all included 
trials, but studies in which the main objective was to evaluate 
different adjuvant endocrine therapies were excluded. Two 
independent reviewers (Paulo Filho and Caroline Albuquerque) 
reviewed the list of citations obtained from the literature search 
and applied the pre-specified eligibility criteria above to selected 
the articles to be included. A third reviewer (Márcio Debiasi) 
adjudicated any discordance.
Data extraction
For each trial, two independent authors (Paulo Filho and 
Caroline Albuquerque) extracted the following data: year of 
publication, sample size, baseline patients’ characteristics, and 
outcomes [hazard ratios (HRs) for OS and DFS]. The Cochrane 
Collaboration risk of bias tool was used to assess studies’ 
quality (24).
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Definition of Treatment Arms
In order to organize the existing treatment options tested in clini-
cal trials in clinically meaningful arms, some general pre-specified 
criteria were used to gather the treatment arms as follows:
ARM 1. chemotherapy alone1
ARM 2. chemotherapy (see text footnote 1)  +  trastuzumab 
12 months
ARM 3. chemotherapy (see text footnote 1)  +  trastuzumab   
≤ 6 months
ARM 4. chemotherapy (see text footnote 1) (taxane + carbopl-
atin) + trastuzumab 12 months
ARM 5. chemotherapy (see text footnote 1)  +  lapatinib 
12 months
ARM 6. chemotherapy (see text footnote 1)  +  trastuzumab 
3 months  lapatinib 9 months (sequential to trastuzumab)
ARM 7. chemotherapy (see text footnote 1)  +  trastuzumab 
12 months + lapatinib2 (concomitant with trastuzumab)
ARM 8. chemotherapy (see text footnote 1)  +  trastuzumab 
12  months  +  pertuzumab (see text footnote 2) (concomitant 
with trastuzumab)
ARM 9. chemotherapy (see text footnote 1)  +  trastuzumab 
12 months  neratinib 12 months (sequential to trastuzumab)
Definition of Outcomes
Overall survival was the primary outcome of this study and was 
similarly defined among studies as the time from randomization 
until death, using an intention to treat analysis. DFS was defined 
as time from randomization to death or any DFS event. Definitions 
of DFS events had slight variations among the trials included and 
are summarized in the Supplementary Material B.
Statistical Methods
Network meta-analysis (also commonly referred to as multiple 
treatment comparison—MTC) is a generalization of classic meta-
analysis that combines direct and indirect evidence to compare 
multiple treatment arms across studies with similar populations 
and outcomes with the proviso that there is at least one linking-
arm between them (22). Direct evidence is defined as the head-
to-head comparison between two treatment arms in a clinical 
trial, while indirect evidence is the estimation of the relative 
effect between two arms that is obtained indirectly through one 
or more common comparators. MTC can be regarded as a gen-
eralized linear model that can be implemented using one out of 
two frameworks: Bayesian or frequentist. The Bayesian approach 
is more commonly used mainly because it is flexible enough to 
analyze a variety of networks of studies (including multi-arm 
trials) and yields, for each treatment arm, posterior probabilities 
estimates that allow ranking the treatment arms in a clinically 
useful manner (21–23, 25–31). These posterior probabilities are 
1 Due to heterogeneity between studies, different chemotherapy backbones were 
accepted (most of which included anthracyclines and taxanes), with the exception 
of the arm #4 (from the BCIRG006 trial) in which all patients received chemo-
therapy with docetaxel + carboplatin.
2 Lapatinib and pertuzumab in these arms were given from 3 to 12 months con-
comitantly with trastuzumab.
calculated based on the HRs for each comparison and their credi-
bility intervals (CrI).
The trials included in this work reported relative treatment 
effects as HRs for OS and DFS. These data were pooled in to two 
separate network meta-analyses, one for each outcome of interest. 
MTC analyses were carried out using the Bayesian approach and 
considering both fixed effect model and random effects with 
homogeneous variability among studies model. Consistency 
assumption was assessed through posterior plots and the Bayesian 
p-values produced by the node splitting method described by 
Dias et al. (29). Results were summarized as point estimates and 
their 95% CrI. HRs were modeled using the software WinBUGS 
(version 1.4.3).
ReSULTS
Our electronic search carried out on January 1, 2018 yielded 1,987 
unique, of which 92 met the inclusion and exclusion criteria for 
this review (accounting for 38 trials in total), of which 18 reported 
OS and/or DFS outcomes. The Figure 1 summarizes the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-
Analysis) chart for the study selection and the supplementary 
material C describes all the trials included in at least one of the 
networks (OS and/or DFS). The risk of bias evaluation of each 
trial was conducted using the Cochrane tool and is described 
in the supplementary material D (24). All closed loops were 
considered simple and no inconsistency was found in any of the 
networks using the “Split Node method” as previously described 
in the statistical section and the subjective analysis of the direct 
and indirect evidences reported (Supplementary Material E).
Overall Survival Network
Fifteen trials published from 2005 to 2017 accounting for 37,837 
patients were included in this network, which is described in 
the Supplementary Material F and in the Figure 2A. The eight 
treatment arms that constitute this network are ranked in Table 1. 
Based on the ordered ranks, the regimens containing CT associ-
ated with trastuzumab and lapatinib (CT + T + L) for 12 months 
are probably the best option for OS, with 62.47% of posterior 
probability of being the best, followed by CT + T + P with 22.06%. 
On the other hand, arms containing chemotherapy without any 
anti-HER2-targeted therapy or CT with lapatinib (with no trast-
uzumab) or CT with trastuzumab for no longer than 6 months are 
probably the worst options, with posterior probabilities of being 
the worst of 85, 6.46, and 4.48%, respectively.
All HRs between treatment arms and their 95% CrI for this 
network are shown in Table 2. This analysis shows that the combi-
nation of CT plus 12 months of dual blockade with trastuzumab 
and lapatinib almost achieved the significance threshold for 
superiority when compared to the standard regimen of CT + T 
for 12 months (HR 0.75; 95% CrI: 0.51–1.01). The comparison 
between the two dual blockade strategies included in this network 
(CT + T + L versus CT + T + P) favored the lapatinib arm but 
was not significant (HR 1.18; 95% CrI: 0.71–2.14).
Other important findings yielded by this analysis are: the 
length of trastuzumab treatment probably impacts negatively on 
FiGURe 2 | Networks for overall survival (OS) and disease-free survival (DFS). (A) OS. (B) DFS. The width of the lines represents the relative weight of the 
direct evidence for a given comparison, based on the number of patients included in trials. ARM 1, chemotherapy alone. ARM 2, chemotherapy +  
trastuzumab 12 months. ARM 3, chemotherapy + trastuzumab ≤ 6 months. ARM 4, chemotherapy (taxane + carboplatin) + trastuzumab 12 months. ARM 5, 
chemotherapy + lapatinib 12 months. ARM 6, chemotherapy + trastuzumab 3 months  lapatinib 9 months (sequential to trastuzumab). ARM 7, 
chemotherapy + trastuzumab 12 months + lapatinib (concomitant with trastuzumab). ARM 8, chemotherapy + trastuzumab 12 months + pertuzumab 
(concomitant with trastuzumab). ARM 9, chemotherapy + trastuzumab 12 months  NERATINIB 12 months (sequential to trastuzumab).
FiGURe 1 | Adapted PRISMA flow diagram. * Indexed literature research: EMBASE, Central (COCHRANE) and PubMed. ** non-indexed literature: American Society 
od Cinical Oncology (ASCO), San Antonio Breast Cancer Symposium (SABCS). European Society for Medical Oncology (ESMO), St. Gallen International Breast 
Cancer Conference.
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OS and the omission of anthracycline did not seem to jeopardize 
treatment efficacy. Six months of anti-HER2 therapy is probably 
inferior to 12  months with an estimated 27% increase in the 
probability of death (HR 1.27; 95% CrI: 0.99–1.59). On the other 
hand, the schedule composed of a taxane without anthracycline 
plus trastuzumab for 1 year (TCH—arm 4) had similar efficacy 
when compared to the standard regimen of CT + T for 12 months 
(HR 1.00; 95% CrI: 0.71–1.64). It is important to emphasize that 
more than 90% of patients included in the CT + T for 12 months 
arm in this comparison did receive an anthracycline-containing 
regimens.
DFS Network
This network is composed of 17 trials, published from 2005 to 
2017, and includes 40,992 patients. The design of this network 
as well as the trials included are summarized in Figure 2B and 
Supplementary Material F, respectively. The ranking of the nine 
included arms and their HRs are summarized in Tables 1 and 
2. Two studies—the ExteNET and the NeoSphere trials—were 
included only in this network, and not in the OS network, because 
they only reported DFS data (13, 32, 33). The inclusion of the 
ExteNET trial to this network brought up that using an additional 
year of neratinib after the standard chemotherapy plus 1 year of 
TABLe 1 | OS and DFS rankings for the (neo)adjuvant treatment strategies available for early and locally advanced HER2 + breast cancer.a
Rank ARM 1 (%) ARM 2 (%) ARM 3 (%) ARM 4 (%) ARM 5 (%) ARM 6 (%) ARM 7 (%) ARM 8 (%) ARM 9 (%)
Disease-free survival Rank 9 95.88 0.00 1.72 0.65 1.61 0.08 0.00 0.01 0.04
Rank 8 3.67 0.00 42.29 6.45 47.08 0.32 0.01 0.05 0.13
Rank 7 0.40 0.39 45.66 11.50 40.31 1.27 0.01 0.22 0.23
Rank 6 0.05 18.28 9.30 48.34 9.83 11.34 0.48 1.23 1.15
Rank 5 0.00 56.38 0.88 16.42 0.91 19.11 1.37 2.71 2.20
Rank 4 0.00 22.80 0.11 10.75 0.24 41.08 7.38 10.89 6.76
Rank 3 0.00 2.04 0.03 4.13 0.01 18.17 35.39 25.51 14.71
Rank 2 0.00 0.10 0.00 1.40 0.01 6.75 34.73 32.78 24.23
Rank 1 0.00 0.01 0.00 0.37 0.00 1.87 20.62 26.59 50.55
Overall survival Rank 1 0.00 0.35 0.09 3.68 0.03 11.32 62.47 22.06 N/A
Rank 2 0.01 5.02 0.37 7.98 0.25 35.09 26.76 24.51 N/A
Rank 3 0.01 26.30 1.28 12.92 1.08 28.63 7.81 21.97 N/A
Rank 4 0.11 48.01 4.29 15.36 2.87 13.82 2.00 13.53 N/A
Rank 5 0.43 18.66 19.30 31.87 10.62 8.11 0.76 10.24 N/A
Rank 6 2.05 1.54 42.90 15.69 31.03 2.26 0.16 4.37 N/A
Rank 7 12.39 0.12 27.29 9.70 47.65 0.56 0.03 2.26 N/A
Rank 8 85.00 0.00 4.48 2.80 6.46 0.22 0.00 1.05 N/A
aThis table indicates the posterior estimates of the probability of each treatment arm being the best (green squares—rank 1) or the worst (red squares—rank 9 for DFS or rank 8 for 
OS).
ARM 1, chemotherapy alone. ARM 2, chemotherapy + trastuzumab 12 months. ARM 3, chemotherapy + Trastuzumab ≤ 6 months. ARM 4, chemotherapy 
(taxane + carboplatin) + trastuzumab 12 months. ARM 5, chemotherapy + lapatinib 12 months. ARM 6, chemotherapy + trastuzumab 3 months  lapatinib 9 months (sequential 
to trastuzumab). ARM 7, chemotherapy + trastuzumab 12 months + lapatinib (concomitant with trastuzumab). ARM 8, chemotherapy + trastuzumab 12 months + pertuzumab 
(concomitant with trastuzumab). ARM 9, chemotherapy + trastuzumab 12 months  neratinib 12 months (sequential to trastuzumab).
TABLe 2 | Mixed treatment comparison hazard ratios (HRs) and their respective 95% CrI for overall survival and disease-free survival (DFA) comparing the (neo)adjuvant 
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aIn this table, the diagonal squares numbered 1–9 represent the nine treatment arms included in the OS and/or DFS networks. By crossing the row and the column of two treatment 
arms in the table, the reader will find the HR for the comparison of these two arms in the corresponding square. HRs were computed considering the hazard of the treatment arm 
assigned the higher number as the numerator and the hazard of the treatment arm assigned the lower number as the denominator (e.g., when comparing the treatment arms 1 and 
2; the reader must consider that it is the hazard of the arm 2 over the hazard of the arm 1).
bCrI that do not cross the non-significance threshold (value 1,0) are highlighted in red.
ARM 1, chemotherapy alone.a ARM 2, chemotherapy + trastuzumab 12 months. ARM 3, chemotherapy + trastuzumab ≤ 6 months. ARM 4, chemotherapy 
(taxane + carboplatin) + trastuzumab 12 months. ARM 5, chemotherapy + lapatinib 12 months. ARM 6, chemotherapy + trastuzumab 3 months  lapatinib 9 months (sequential 
to trastuzumab). ARM 7, chemotherapy + trastuzumab 12 months + lapatinib (concomitant with trastuzumab). ARM 8, chemotherapy + trastuzumab 12 months + pertuzumab 
(concomitant with trastuzumab). ARM 9, chemotherapy + trastuzumab 12 months  neratinib 12 months (sequential to trastuzumab).
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trastuzumab is probably the best treatment option for this out-
come, with 50.55% of posterior probability of this arm being the 
best one (Table 1). Most of the other findings observed at the OS 
network were confirmed in the DFS network.
DiSCUSSiON
It is well established that CT plus trastuzumab is the backbone for 
the adjuvant and neoadjuvant treatment of the HER2+ early and 
locally advanced breast cancer patients. This statement is based 
on a robust body of evidence that comes from several phase III 
randomized clinical trials and meta-analyses (34). However, 
uncertainties in the management of HER2+ breast cancer 
patients remain, such as the optimal chemotherapy regimen that 
should be administered with trastuzumab and the length of 
trastuzumab therapy, although the empiric 1-year duration is 
the standard of care. Recently, the FDA-approved dual block-
ade with trastuzumab plus pertuzumab as well as 1 year of 
neratinib after the completion of 1 year trastuzumab (11, 13). 
Additionally, different strategies to inhibit the HER2-pathway, 
such as those with pertuzumab, lapatinib, and neratinib, have 
already been tested creating multiple possible comparisons, 
which cannot be assessed by classical meta-analysis meth-
odology and have not been tested in proper head-to-head 
comparisons. The present work is the first to model HRs for 
time-to-event outcomes (OS and DFS) in unique mathemati-
cal models (Mixed Comparison Treatment network meta-
analysis—MTC) that include all the available evidence on this 
matter.
No inconsistencies were found in either of the networks, as 
presented in the Supplementary Material E. An additional finding 
that corroborates the robustness of the data presented here is that 
this analysis identified a HR of 0.62 (95% CrI:0.52–0.78) for the 
comparison between chemotherapy alone versus chemotherapy 
plus one year of trastuzumab, which is very close to the results 
found in a Cochrane meta-analysis (0.66; 95% CI 0.57–0.77) 
(33). The slightly better results observed in the present analysis 
can be explained by the fact that all patients in this comparison 
used 1  year of trastuzumab, while the Cochrane meta-analysis 
considered together patients that received trastuzumab for 1 year 
and for less than 6 months (33).
The concept of the dual blockade was proven in this analysis. 
In the OS network, regimens containing CT plus trastuzumab 
and lapatinib were probably the best treatment options in this 
scenario, followed by CT plus trastuzumab and pertuzumab, 
with posterior probabilities of these regimes being the best of 
62.47 and 22.06%, respectively. Questions still remain on this 
subject, because OS has not yet been published for neratinib and 
is not yet fully mature for the adjuvant pertuzumab study, the 
Aphinity Trial. However, these results are robust in showing the 
benefit of the dual blockade for early breast cancer patients. This 
finding might seem somehow unexpected given the negative OS 
results of the ALTTO trial. However, one should note that sample 
size for this trial was calculated for DFS and the number of events 
are lower than expected by the inclusion of low risk patients (40% 
node-negative and 40% small tumors) (555 DFS events instead of 
the 850 expected events in the first report) (35, 36). The mature 
OS results of the trials studying trastuzumab plus pertuzumab 
are expected in the future and may help further supporting dual 
anti-HER2 blockade in women with curable HER2+ breast 
cancer.
The positive results of the dual blockade were also confirmed 
in the DFS network analysis. However, it is important to note that 
this network counted with an extra arm of sequential neratinib 
after the standard CT + T from the ExteNET trial and that this 
arm was probably the best one for this outcome. After this analysis, 
CT associated with 12 months of trastuzumab might still be the 
standard treatment for HER2 + early or locally advanced breast 
cancer patients, though there is a strong suggestion that dual 
blockade is superior and pertuzumab and neratinib have been 
approved by the FDA in the adjuvant setting. Despite the negative 
results of the ALTTO trial, the point estimate in this randomized 
clinical trial showed benefit and, as discussed before, there might 
be some conservative bias in the analysis of the results.
CONCLUSiON
In the era of personalized medicine, HER2-positive breast cancer 
turned to be a curable disease with multiple effective treatment 
options creating an urgent need for more comprehensive meth-
ods for data analysis and biomarkers to select the right treatment 
for the right patient. This network meta-analysis suggests that 
combining trastuzumab with either lapatinib or pertuzumab 
is probably the best strategy in terms of OS gain in this clini-
cal scenario. However, at this moment, only the combination 
of trastuzumab and pertuzumab as adjuvant treatment has 
been FDA approved. Mature OS results are still expected for 
the Aphinity trial and for the sequential use of trastuzumab 
followed by neratinib (the treatment strategy that have shown the 
best results in terms of DFS in our analysis). As evidence-based 
medicine evolves, analyses from complex networks of trials must 
be combined with the patient’s individual risk of recurrence, 
safety profile, and patient’s preferences to support choices in an 
evidence-based clinical practice.
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